Table 1.

Patient characteristics.

Variable	nal-IRI + 5-FU/LV (n = 86)
Gender
Male	52 (60.5%)
Female	34 (39.5%)
Age, median (range)	61 (37–79)
<65	55 (64.0%)
⩾65	31 (36.0%)
Primary tumour site
Head	41 (47.7%)
Body	17 (19.8%)
Tail	27 (31.4%)
Multi-centric	1 (1.2%)
Site of metastasis
Liver	49 (57.0%)
Lung	27 (31.4%)
Bone	4 (4.7%)
Peritoneum	30 (34.9%)
Lymph node	21 (24.4%)
Other	15 (17.4%)
Baseline CA 19-9 level (U/ml), median (range)	844 (1.2–124,073)
⩽1 × UNL	12 (14.0%)
>1 and ⩽2 × UNL	4 (4.7%)
>2 × UNL	55 (64.0%)
N/A	15 (17.4%)
Prior surgical resection	39 (45.3%)
Prior concurrent chemoradiotherapy	20 (23.3%)
Prior lines of palliative chemotherapy, median (range)	2 (0–4)
0	8 (9.3%)
1	27 (31.4%)
2	36 (41.9%)
3	12 (14.0%)
4	3 (3.5%)
Prior first-line palliative chemotherapy	n = 78
Gemcitabine monotherapy	12 (14.0%)
Gemcitabine plus nab-paclitaxel	44 (51.2%)
FOLFIRINOX	14 (16.3%)
Others	8 (9.3%)
Prior irinotecan-containing chemotherapy (FOLFIRINOX)	18 (20.9%)
Prior gemcitabine plus nab-paclitaxel chemotherapy	51 (59.3%)
Prior 5-FU/LV containing chemotherapy	59 (68.6%)

CA 19-9, carbohydrate antigen 19-9; UNL, upper normal limit; N/A, not available.